

## B18R Recombinant Protein Carrier-Free

**Catalog Number:** 34-8185

**Also Known As:** Vaccinia Virus-Encoded Neutralizing Type I Interferon Receptor; Type I IFN inhibitor

**RUO: For Research Use Only. Not for use in diagnostic procedures.**

### Product Information

**Contents:** B18R Recombinant Protein Carrier-Free

**REF** **Catalog Number:** 34-8185

**Handling Conditions:** For best recovery, quick-spin vial prior to opening. Use in sterile environment.

**Source:** Insect cells infected with baculovirus: amino acids His20-Glu 351 with a His-tag attached of Vaccinia Virus B18R accession # D01019

**Molecular Mass:** The polypeptide has a predicted molecular mass of 38,389. The DTT-reduced protein migrates as a 48 kDa polypeptide on SDS-PAGE due to glycosylation. The non-reduced protein migrates as a 46 kDa polypeptide on SDS-PAGE due to internal cysteines.

**Purity:** > 98%, as determined by SDS-PAGE.

**Endotoxin Level:** Less than 0.05 ng/ug cytokine as determined by the LAL assay.

**Bioactivity:** The ND50 of this protein, as measured by neutralization of Mouse IFN alpha 2 Recombinant Protein, is less than or equal to 800 pg/mL in the presence of 1 ng/mL Mouse IFN alpha 2. This corresponds to a specific activity of greater than or equal to 1.3 x 10<sup>6</sup> Units/mg.

**Formulation:** Sterile liquid; 10 mM phosphate, 0.5 M NaCl, pH 7.5



**Temperature Limitation:** Store at less than or equal to -70°C.



**Batch Code:** Refer to Vial



**Use By:** Refer to Vial

### Description

The B18R protein is a vaccinia virus-encoded receptor with specificity for mouse, human, rabbit, pig, rat, and cow type I interferons which has potent neutralizing activity. B18R that acts as a decoy receptor for Type I Interferons (IFN $\alpha$ , IFN $\beta$ , IFN $\epsilon$ , k, t, d, z, w, v). B18R was recently identified to enable increased cell viability during RNA transfection protocols designed to convert human somatic donor cells into iPSCs via direct delivery of modified synthetic mRNAs for OCT4, SOX2, KLF4 and MYC (OSKM) and Lin28 with the aim to enable highly efficient reprogramming of somatic cells to pluripotency. This allows for re-directed differentiation toward a desired lineage while removing the risk of genomic integration and insertional mutagenesis inherent to DNA-bases methodologies and eliminates the need for virus-based approaches. iPSCs represent a widely available, non-controversial and practically infinite source of pluripotent cells.

The B18R protein is a type I interferon receptor encoded by the B18R gene of the Western Reserve vaccinia virus strain. The 60-65 kD glycoprotein is related to the interleukin-1 receptors and is a member of the immunoglobulin superfamily, unlike other type I IFN-receptors, which belong to the class II cytokine receptor family. The B18R protein has a high affinity (KD, 174 pM) for human IFN alpha and, unlike other type I IFN receptors, has broad species specificity, binding to type I interferons of human, mouse, rat, rabbit, pig, and cow. Among viral host response modifiers, the B18R protein is unique in that it exists as a soluble extracellular, as well as a cell surface protein, enabling blockage of both autocrine and paracrine IFN functions. The B18R protein has been shown to inhibit the antiviral potency of IFN-alpha1, IFN-alpha2, IFN-alpha-8/1/8, and IFN-omega on human cells. The soluble B18R protein is highly potent for neutralizing type I interferons, which include IFN-alpha, beta, delta, kappa. Please note effects on mouse IFNs vary from other species; it has been shown that B18R does not neutralize mouse IFN beta.

### Applications Reported

Recombinant B18R is fully biologically active.

### Applications Tested

This recombinant B18R protein (type I IFN receptor) has been tested in bioassay for neutralization of mouse and human interferons ( $\alpha$  and  $\beta$ ). Human IFN: Pre-incubation of recombinant human IFN- $\alpha$ 2a with 0.1  $\mu$ g/ml B18R for 1 hr at RT was found to neutralize completely the activity of 1 ng/ml IFN- $\alpha$ 2a.

Mouse IFN: In an assay of EMCV infection of L929 cells, pre-incubation of recombinant mouse IFN- $\alpha$ A with 250.0 picograms/ml B18R for 1 hr at RT was found to neutralize completely the activity of 5 pg/ml (1 Unit) mIFN- $\alpha$ A. The ND50 of this protein, as measured by neutralization of Mouse IFN alpha 2 Recombinant Protein, is less than or equal to 800 pg/mL in the presence of 1 ng/mL Mouse IFN alpha 2. This corresponds to a specific activity of greater than or equal to 1.3 x 10<sup>6</sup> Units/mg.

### References

Mandal PK, Rossi DJ Reprogramming human fibroblasts to pluripotency using modified mRNA. Nature Protocols. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. 2013 Feb; 8(3):568-82.

Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C,

Schlaeger TM, Rossi DJ. Cell Stem Cell. 2010 Nov 5;7(5):618-30.

Symons JA, Alcamí A, Smith GL. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell. 1995 May 19;81(4):551-60.

Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM.. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem. 1995 Jul 7;270(27):15974-8.

Vancová I, La Bonnardiere C, Kontsek P. Vaccinia virus protein B18R inhibits the activity and cellular binding of the novel type interferon-delta. J Gen Virol. 1998 Jul;79 ( Pt 7):1647-9.

Meyers JA, Mangini AJ, Nagai T, Roff CF, Sehy D, van Seventer GA, van Seventer JM. Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC. Cytokine. 2006 Sep;35(5-6):235-46. (B18R, BA PubMed)

---

Not for further distribution without written consent.

Copyright © 2000-2012 eBioscience, Inc.

Tel: 888.999.1371 or 858.642.2058 • Fax: 858.642.2046 • [www.eBioscience.com](http://www.eBioscience.com) • [info@eBioscience.com](mailto:info@eBioscience.com)